AstraZeneca Buys Collaboration Partner Omniose to Own Its Bioconjugate Vaccine Platform
- AstraZeneca acquired Omniose, a preclinical biotech whose platform assembles conjugate vaccines inside an engineered cell rather than through multi-step chemistry.
- Omniose becomes a wholly owned subsidiary within AstraZeneca's infectious disease unit; financial terms were not disclosed.
- The two had collaborated on vaccines against drug-resistant bacteria since January 2024.
💡 Points Based on public reports
Buying a partner you already work with is a classic de-risk-then-own move, and an undisclosed price suggests a small, platform-driven deal. Bacterial conjugate vaccines are where Pfizer and GSK are established, so the question is whether cell-based assembly is cheaper and more modular than chemical conjugation. Nothing clinical yet: this is a manufacturing and platform bet.
📰 Source · Fierce Biotech ↗ AstraZeneca buys partner Omniose for bacterial vaccine technology